Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrikfene versus sufentanil for digestive endoscopic anesthesia in elderly patients
ChiCTR2600133400Phase 4Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Oct 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of hsk21542, sufentanil and ciprofol in None (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Incidence of adverse reactions. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
hsk21542sufentanilciprofol
Beyond the preview
Go deeper on ChiCTR2600133400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133400.